NICE Issues Favorable Final Draft Guidance On Sanofi-Aventis' Multaq
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE's final appraisal determination on Sanofi-Aventis' Multaq recommends limited use in U.K. atrial fibrillation patients. In France, more favorable ratings by the Transparency Commission might mean a better price.